Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Core Viewpoint - Ultragenyx Pharmaceutical Inc. has faced setbacks following the announcement of topline results from its Phase III Orbit and Cosmic Studies, which did not meet primary endpoints for the effectiveness of setrusumab (UX143) on Osteogenesis Imperfecta [1][2]. Group 1: Study Results - The Phase III Orbit and Cosmic Studies failed to achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo and standard care, respectively [2]. - Despite showing improvements in bone density among tested patients, the studies did not correlate these results with a reduction in fracture rates [3]. Group 2: Company Response and Analyst Reactions - In response to the study results, Ultragenyx management cited a "low fracture rate in the placebo group" as a reason for the failed outcomes, asserting that the study was designed to increase fracture occurrences to better observe differences between test groups [3]. - Following the announcement, analysts became cautious, with Barclays indicating limited opportunity for drug approval despite some clinical benefits observed [4].